Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab in Patients With Melanoma
NCT04930783Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Modality
- Cytokines & Interferons, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoVax and Flt3 ligand in melanoma (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Rate of Dose Limiting Toxicity at 49 days and Recommended maximum tolerated dose at 12 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
NeoVaxFlt3 ligand
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04930783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930783.